Is banning texturized implants to prevent breast implant-associated anaplastic large cell lymphoma a rational decision? A meta-analysis and cost-effectiveness study
Author
dc.contributor.author
Danilla, Stefan V.
Author
dc.contributor.author
Jara, Rocío P.
Author
dc.contributor.author
Miranda, Felipe
Author
dc.contributor.author
Bencina, Francisco
Author
dc.contributor.author
Aguirre, Marcela
Author
dc.contributor.author
Troncoso, Ekaterina
Author
dc.contributor.author
Erazo, Cristian A.
Author
dc.contributor.author
Andrades, Patricio R.
Author
dc.contributor.author
Sepúlveda, Sergio L.
Author
dc.contributor.author
Albornoz, Claudia R.
Admission date
dc.date.accessioned
2021-08-04T23:05:36Z
Available date
dc.date.available
2021-08-04T23:05:36Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
Aesthetic Surgery Journal 2020, Vol 40(7) 721–731
es_ES
Identifier
dc.identifier.other
10.1093/asj/sjz343
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/181093
Abstract
dc.description.abstract
Background: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an emergent disease that threatens
patients with texturized breast implants. Major concerns about the safety of these implants are leading to global changes
to restrict the utilization of this product. The principal alternative is to perform breast augmentation utilizing smooth implants,
given the lack of association with BIA-ALCL. The implications and costs of this intervention are unknown.
Objectives: The authors of this study determined the cost-effectiveness of smooth implants compared with texturized
implants for breast augmentation surgery.
Methods: A tree decision model was utilized to analyze the cost-effectiveness. Model input parameters were derived
from published sources. The capsular contracture (CC) rate was calculated from a meta-analysis. Effectiveness measures
were life years, avoided BIA-ALCL, avoided deaths, and avoided reoperations. A sensitivity analysis was performed to test
the robustness of the model.
Results: For avoided BIA-ALCL, the incremental cost was $18,562,003 for smooth implants over texturized implants.
The incremental cost-effectiveness ratio was negative for life years, and avoided death and avoided reoperations were
negative. The sensitivity analysis revealed that to avoid 1 case of BIA-ALCL, the utilization of smooth implants would be
cost-effective for a risk of developing BIA-ALCL equal to or greater than 1:196, and there is a probability of CC with smooth
implants equal to or less than 0.096.
Conclusions: The utilization of smooth implants to prevent BIA-ALCL is not cost-effective. Banning texturized implants to
prevent BIA-ALCL may involve additional consequences, which should be considered in light of higher CC rates and more
reoperations associated with smooth implants than with texturized implants.
Is banning texturized implants to prevent breast implant-associated anaplastic large cell lymphoma a rational decision? A meta-analysis and cost-effectiveness study